Teva’s innovation engine offsets generics slump, leaving one analyst ‘shocked’ by Ajovy’s surge

As Teva proceeds down the more muted growth path that it telegraphed early this year, the generics and innovative medicines hybrid isn’t letting a little sales slump affect its confidence in a budd | As Teva proceeds down the more muted growth path that it telegraphed early this year, the generics and innovative medicines hybrid isn’t letting a little sales slump affect its confidence in a budding portfolio of branded drugs.

Raccontata dafiercepharma.cominvestors.com